Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Cancer Metastatic × Nivolumab × Thoracic × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 212 Lung Neoplasms 66 Melanoma 49 Carcinoma, Renal Cell 39 Small Cell Lung Carcinoma 29 Colorectal Neoplasms 23 Squamous Cell Carcinoma of Head and Neck 22 Neoplasms 22 Carcinoma, Transitional Cell 22 Triple Negative Breast Neoplasms 20 Neoplasm Metastasis 19 Carcinoma, Hepatocellular 16 Mesothelioma 15 Ovarian Neoplasms 14 Mesothelioma, Malignant 14 Pancreatic Neoplasms 13 Stomach Neoplasms 12 Breast Neoplasms 12 Uterine Cervical Neoplasms 10 Head and Neck Neoplasms 10 Urinary Bladder Neoplasms 9 Carcinoma, Merkel Cell 9 Kidney Neoplasms 8 Adenocarcinoma of Lung 7 Esophageal Neoplasms 6 Endometrial Neoplasms 6 Carcinoma, Squamous Cell 6 Brain Neoplasms 6 Lymphoma 5 Gastrointestinal Neoplasms 5

Interventions

tremelimumab 1 regramostim 1 osimertinib 1 evolocumab 1 durvalumab 1 Surgical Instruments 1 Radiotherapy 1 Radiation 1 Nivolumab 1 Needles 1 MLN 8237 1 Ipilimumab 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05144529 2025-04-17

TOP2101

Duke University

Phase 2 Active not recruiting

Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡